TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$173 Million

Personalis, Inc.

Follow-on Offering

Bookrunner, January 2021

Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. Personalis designed its NeXT Platform to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contract to many cancer panels that cover roughly 50 to 500 genes.